

October 16, 2014
SEIKAGAKU CORPORATION
(Securities Code: TSE 4548)

Seikagaku Announces the Opening of the SEIKAGAKU U.S.A. Representative Office

Seikagaku Corporation (Tokyo, Japan) today announces that it has opened the SEIKAGAKU U.S.A. Representative Office in Jersey City, New Jersey, U.S.A.

Seikagaku is promoting its pharmaceuticals business in the United States where, in 2001, it launched its multiple-injection joint function improving agent, SUPARTZ[®], and in 2012, commenced full-scale sales of its single-injection joint function improving agent, Gel-One[®].

An increase in the aged population in the United States has led to higher numbers of knee osteoarthritis patients, and further expansion of the market for hyaluronic acid formulations is expected. By opening a representative office, Seikagaku aims to strengthen its support for the activities of its local sales partners, improve information gathering about the U.S. market, and enhance the market presence of Seikagaku products.

An overview of SEIKAGAKU U.S.A. Representative Office is as follows.

Name: SEIKAGAKU U.S.A. Representative Office

Address: 15 Exchange Place, Jersey City, New Jersey 07302, U.S.A.

Description of operations: supporting sales partners' activities, gathering of information about the U.S. market, etc.

Date of opening: October 15, 2014 (local time)

#####